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Abstractͳ͹
Influenza A virus (IAV) entry is a multi-step process that requires the interaction ͳͺ
of the virus with numerous host factors. In this study, we demonstrate that ͳͻ
prolidase (PEPD) is a cellular factor required by IAV for successful entry into ʹͲ
target cells. PEPD was selected as a candidate during an entry screen ʹͳ
performed on non-validated primary hits from previously published genome-wide ʹʹ
siRNA screens. siRNA-mediated depletion of PEPD resulted in decreased ʹ͵
growth of IAV during mono- and multi-cycle growth. This growth defect was ʹͶ
independent of cell type or virus strain. Furthermore, IAV restriction was apparent ʹͷ
as early as 3h post-infection and experiments in the absence of protein ʹ͸
biosynthesis revealed that nuclear import of viral ribonucleoprotein complexes ʹ͹
(vRNPs) was already blocked in the absence of PEPD. These results led us to ʹͺ
investigate which step during entry was affected. Receptor expression, IAV ʹͻ
attachment or internalization were not dependent on the presence of PEPD.  ͵Ͳ
However, when looking at the distribution of incoming IAV particles in PEPD ͵ͳ
knockdown cells, we found a localization pattern that differed compared to ͵ʹ
control cells: IAV mostly localized to the cell periphery and consequently, viral ͵͵
particles displayed reduced co-localization with early and late endosome markers ͵Ͷ
and fusion between viral and endosomal membranes was strongly reduced. ͵ͷ
Finally, experiments using a competitive inhibitor of PEPD catalytic activity ͵͸
suggest that the enzymatic function of the dipeptidase is required for its proviral ͵͹
effect on IAV entry. In sum, this study establishes PEPD as a novel entry factor ͵ͺ
required for early endosomal trafficking of IAV. ͵ͻ
ʹ

ImportanceͶͲ
Influenza A virus (IAV) continues to be a constant threat to public health. As IAV Ͷͳ
relies on its host cell for replication the identification of host factors required by Ͷʹ
the virus is of importance: First, such studies often reveal novel functions of Ͷ͵
cellular factors and can extend our knowledge of cellular processes. Second, we ͶͶ
can further our understanding of processes that are required for entry of IAV into Ͷͷ
target cells. Third, the identification of host factors that contribute to IAV entry will Ͷ͸
enlarge the number of potential targets for the development of novel antiviral Ͷ͹
drugs that are of urgent need. Our study identifies prolidase (PEPD) as a novel Ͷͺ
entry factor of IAV required for correct routing within the endosomal compartment Ͷͻ
following virus internalization. Thereby, we link PEPD which has been shown to ͷͲ
play a role during collagen recycling and growth factor signaling, to early events ͷͳ
of viral infection.ͷʹ
ͷ͵
͵

IntroductionͷͶ
Influenza A virus (IAV), causes an acute febrile illness in humans generally ͷͷ
referred to as the flu. The virus is responsible for causing annual epidemics and ͷ͸
occasional pandemics which pose a threat to public health and a large economic ͷ͹
burden on society. IAV belongs to the family of Orthomyxoviridae and contains a ͷͺ
segmented, single-stranded RNA genome of negative polarity (1). IAV virions are ͷͻ
enveloped and four membrane-associated proteins have been described: ͸Ͳ
Hemagglutinin (HA), Neuraminidase (NA), the Matrix protein 2 (M2) ion channel ͸ͳ
(1) and the M2-related protein M42 (2). While NA is required for budding and ͸ʹ
release of viral progeny from infected cells, HA and M2 mediate entry of IAV ͸͵
virions into target cells which are thought to be primarily epithelial cells of the ͸Ͷ
respiratory tract expressing sialic acid (3). Entry of IAV is a dynamic multi-step ͸ͷ
process that can be divided into several distinctive stages: attachment to the cell ͸͸
surface, internalization, endosomal transport of virions towards the perinuclear ͸͹
region, fusion, uncoating and import of the viral ribonucleoprotein complexes ͸ͺ
(vRNPs) into the nucleus (4). The receptor for IAV attachment is sialic acid (1). ͸ͻ
HA binds to sialic acid residues present on many cell-surface glycoproteins which ͹Ͳ
triggers uptake of virions into target cells. Internalization occurs mainly via ͹ͳ
clathrin-mediated endocytosis (5-7) but also alternative pathways such as ͹ʹ
macropinocytosis have been proposed (8, 9). The pH-drop that occurs during the ͹͵
maturation process from early endosomes (EE) to late endosomes (LE) is ͹Ͷ
required for a conformational change of HA which mediates fusion of viral and ͹ͷ
endosomal membranes (10-12). Simultaneously, the M2 ion channel allows flux ͹͸
Ͷ

of protons from the endosomal compartment into the virion core (13). The ͹͹
resulting acidification of the virion is required for release of the vRNPs into the ͹ͺ
cytoplasm, a process referred to as uncoating (14). Finally, vRNPs are imported ͹ͻ
into the nucleus, the site of viral replication, via the karyopherin transport ͺͲ
pathway (1, 15).ͺͳ
Vaccines against IAV are available and are the best option at present to prevent ͺʹ
seasonal epidemics. However, these vaccines induce only short-lived protection ͺ͵
against a small set of viruses. They do not provide protection against new strains ͺͶ
of IAV that occasionally arise in the human population. For such a scenario it is ͺͷ
crucial to have anti-influenza virus drugs available. Currently, there are two ͺ͸
different classes of antiviral drugs approved for the use in humans. One class are ͺ͹
the adamantanes which target the M2 ion channel thereby preventing uncoating ͺͺ
(16-18). The second class of drugs targets NA and inhibits egress of the virus ͺͻ
from the host cell (19, 20). Unfortunately, resistance of IAV against these drugs ͻͲ
has become a major problem such that the adamantanes are not recommended ͻͳ
for the use in humans anymore (21). In addition, virus strains resistant against ͻʹ
NA inhibitors have been reported (22). These developments emphasize the ͻ͵
urgent need for novel antiviral treatment options. To circumvent the problem of ͻͶ
resistance and to increase the number of potential targets of novel antivirals, ͻͷ
several studies are currently directed towards finding cellular proteins instead of ͻ͸
viral proteins as drug targets. Genome-wide siRNA screens are a powerful tool to ͻ͹
identify host factors associated with viral infections. Several such screens have ͻͺ
been performed to determine cellular factors required by IAV during infection (23-ͻͻ
ͷ

30). Surprisingly, there was hardly any overlap between the primary hits ͳͲͲ
identified in these screens (31). Responsible for these discrepancies are likely ͳͲͳ
the different experimental designs as well as the selection criteria and validation ͳͲʹ
methodologies applied in the screens. This complicates the comparison between ͳͲ͵
hits from different screens and may account for the small overlap observed. For ͳͲͶ
follow-up studies, the factors that show up in several screens are thus far the ͳͲͷ
best candidates. In this study, we aimed to revisit the overlapping primary hits ͳͲ͸
from the different screens that had not been validated yet and screen them for a ͳͲ͹
role during IAV entry. We identified PEPD, a cytosolic dipeptidase, as a novel ͳͲͺ
entry factor of IAV and show that the distribution of incoming viruses was altered ͳͲͻ
in cells lacking PEPD and that there were fewer viruses present in the ͳͳͲ
endosomal compartment. These data indicate that the routing of IAV following ͳͳͳ
internalization is likely to be dependent on PEPD. Finally, we show that the ͳͳʹ
catalytic activity of PEPD may be required for the observed pro-viral effect of ͳͳ͵
PEPD on IAV entry.ͳͳͶ
ͳͳͷ
͸

Materials and Methods ͳͳ͸
Cells, viruses, and compounds. A549, MDCK and WI38 cell lines were ͳͳ͹
maintained in 10% FCS-supplemented DMEM containing penicillin/streptomycinͳͳͺ
(Life Technologies). Influenza virus strain A/WSN/33 was grown in A549 cells, ͳͳͻ
while A/Hong Kong/68, FPV/Dobson and A/Panama/2007/99 were grown in ͳʹͲ
embryonated chicken eggs. A/Netherlands/602/2009 was grown in MDCK cells. ͳʹͳ
Purified A/PR/8/34 was purchased from Charles River. All influenza virus stocks ͳʹʹ
were titered by plaque assay using Vero or MDCK cells. Virus-like particles (VLP) ͳʹ͵
were generated by transfecting 293T cells with a plasmid containing an HIV ͳʹͶ
provirus encoding Gaussia luciferase, an HIV gag-pol expression plasmid and ͳʹͷ
plasmids coding for the respective viral glycoproteins (WSN-HA/NA, LASV-GP or ͳʹ͸
MLV-Env) using jetPRIME (Polyplus transfection) (28). The following compounds ͳʹ͹
were used: Bafilomycin A1 (Sigma-Aldrich), N-Benzyloxycarbonyl-L-proline ͳʹͺ
(Chemos GmbH), cycloheximide (Sigma-Aldrich), recombinant PEPD (Abnova) ͳʹͻ
and IFN-alfa 2a from Roche (Roferon-A).ͳ͵Ͳ
siRNA transfections and cell viability assay. Cells were transfected in ͳ͵ͳ
suspension with 30 nM siRNA (Qiagen) diluted in Opti-MEM (Life Technologies) ͳ͵ʹ
using RNAimax (Invitrogen). 48h post-transfection cells were either infected or ͳ͵͵
cell viability was determined using CellTiter-Glo (Promega). For siRNA and DNA ͳ͵Ͷ
co-transfection, A549 cells were transfected with 30nM siRNA and 200ng of ͳ͵ͷ
plasmid DNA diluted in Opti-MEM using Lipofectamine 2000 reagent (Life ͳ͵͸
Technologies).ͳ͵͹
ͳ͵ͺ
͹

Entry screen and virus-like particle infection. Per factor, four siRNAs (Qiagen, ͳ͵ͻ
see suppl. Table 1) were used for transfection into A549 cells. Only two siRNAs ͳͶͲ
per gene were used if siRNAs were functionally verified by Qiagen. 48h post-ͳͶͳ
transfection, cells were infected with VLPs diluted in Opti-MEM for 1h at 37ºC. ͳͶʹ
Cells were washed with phosphate-buffered saline (PBS) and then kept in DMEM ͳͶ͵
supplemented with 10% FCS and penicillin/streptomycin for 30h at 37ºC. ͳͶͶ
Luciferase activity in the supernatants was determined using the Renilla ͳͶͷ
Luciferase Assay System (Promega). siRNAs that induced reductions in cell ͳͶ͸
viability of more than 30% compared to siScr treatment were excluded from the ͳͶ͹
analysis. The quality of reduction in IAV VLP entry was scored based on the ͳͶͺ
fulfillment of the following criteria: A reduction in IAV VLP entry of more than 50% ͳͶͻ
compared to control, while LASV or MLV VLP entry was higher than 50% scored ͳͷͲ
1. To score 2, luciferase counts had to be below 30% compared to control for IAV ͳͷͳ
VLPs while the reduction for either LASV or MLV VLPs was less than 70%. ͳͷʹ
Finally, the highest score of 3 was given if siRNA-transfection resulted in ͳͷ͵
reductions of IAV VLP entry of more than 70% of the control values while LASV ͳͷͶ
or MLV VLP entry was not reduced more than 50% compared to siScr-treated ͳͷͷ
cells. A gene was considered an entry factor if at least 2 siRNAs fulfilled one of ͳͷ͸
the three criteria. With these criteria we aimed to find IAV-specific host factors. ͳͷ͹
We included scoring of control VLPs (LASV and MLV) because effects on the ͳͷͺ
luciferase activity following infection with these VLPs would indicate either ͳͷͻ
general effects on viral entry mechanisms or effects on the retroviral steps during ͳ͸Ͳ
this assay. Next, the sum of all scores obtained for a given factor was calculated. ͳ͸ͳ
ͺ

This was then multiplied with the ratio (R) of the number of successful siRNAs to ͳ͸ʹ
the total number of siRNAs tested for a given factor.  ͳ͸͵
Influenza A virus infection. A549 or WI38 cells were washed once with PBS, ͳ͸Ͷ
then infected with the respective amount of virus diluted in PBS supplemented ͳ͸ͷ
with 0.02 mM Mg2+, 0.01 mM Ca2+, 0.3% bovine serum albumin (BSA) and 1% ͳ͸͸
penicillin/streptomycin (infection PBS) at 37°C for 1h before changing to DMEM ͳ͸͹
containing 0.3% BSA, 20 mM HEPES and 1% penicillin/streptomycin (post-ͳ͸ͺ
infection DMEM). With the exception of A/WSN/33 all virus strains were grown in ͳ͸ͻ
the presence of 0.25 ug/ml TPCK trypsin (Sigma-Aldrich). Virus titers in tissue ͳ͹Ͳ
culture supernatants were determined by standard plaque assay on Vero or ͳ͹ͳ
MDCK cells.ͳ͹ʹ
ͳ͹͵
Western blotting. Cell extracts were prepared using Laemmli buffer (62.5 mM ͳ͹Ͷ
Tris-HCl pH 6.8, 25% glycerol, 2% SDS, 350mM DTT, 0.01% Bromophenol ͳ͹ͷ
Blue). Samples were subjected to standard SDS-PAGE and proteins were ͳ͹͸
transferred to nitrocellulose membranes (Hybond ECL, GE Healthcare). For ͳ͹͹
blocking, 5% milk diluted in Tris-buffered saline containing 0.5% Tween 20 was ͳ͹ͺ
used. The following primary antibodies were used: rabbit monoclonal anti-PEPD ͳ͹ͻ
(Abcam, ab86507); mouse monoclonal anti-MxA (kind gift of J. Pavlovic); mouse ͳͺͲ
monoclonal anti-ȕ-actin (Santa Cruz Biotechnology, sc-47778); rabbit polyclonal ͳͺͳ
anti-NP (kind gift of A. Nieto); mouse monoclonal anti-M1 (kind gift of J. ͳͺʹ
Pavlovic).ͳͺ͵
ͻ

Immunofluorescence. To synchronize infection, A549 cells were infected with ͳͺͶ
A/WSN/33 on ice for 1h. Then, cells were shifted to 37ºC for the indicated times ͳͺͷ
to allow infection to proceed. For NP staining, cells were fixed with 3.7% ͳͺ͸
paraformaldehyde (PFA) in PBS, permeabilized with 0.5% Triton-X-100 and ͳͺ͹
blocked with 2% bovine albumine. Cells were incubated with mouse monoclonal ͳͺͺ
anti-NP (kind gift of J. Pavlovic). The NP/EEA1 or LBPA co-staining was ͳͺͻ
performed in PBS supplemented with 50 mM NH4Cl, 0.1% saponin and 2% ͳͻͲ
bovine albumine (confocal buffer). The following primary antibodies diluted in ͳͻͳ
confocal buffer were used: rabbit monoclonal anti-NP (kind gift of P. Palese); ͳͻʹ
mouse monoclonal anti-EEA1 (BD Biosciences) and mouse monoclonal anti-ͳͻ͵
LBPA (Echelon), followed by secondary antibodies (Life Technologies, A-21121, ͳͻͶ
A-21134 and A-11008). Nuclei were visualized using DAPI (Life Technologies) or ͳͻͷ
DAPI Fluoromount G (Southern Biotech #0100-20). For labeling acidic organelles ͳͻ͸
a Lysotracker system was used (Life Technologies Lysotracker Red DND-99, ͳͻ͹
L7528). Images were acquired with a Leica SP5 confocal laser-scanning ͳͻͺ
microscope. Image processing was performed using LAS AF lite Software ͳͻͻ
(Leica), Imaris (co-localization and z-stack analysis) and ImageJ (nuclear signal ʹͲͲ
intensity analysis and fusion site analysis). A Mann-Whitney test was used to test ʹͲͳ
for significant differences in mean nuclear fluorescence intensity. ʹͲʹ
Internalization assay and FACS. A/WSN/33 was concentrated over a sucrose ʹͲ͵
cushion (30%) and biotinylated using the EZ-link NHS-SS Biotin kit (Thermo ʹͲͶ
Scientific). siRNA-transfected A549 cells were detached (EDTA-Trypsin, Life ʹͲͷ
Technologies) and cooled down in FACS buffer (PBS supplemented with 2% ʹͲ͸
ͳͲ

BSA) on ice. Cells were infected on ice with biotinylated A/WSN/33 for 1h and ʹͲ͹
washed thoroughly with FACS buffer. Before cells were incubated at 37ºC for 30 ʹͲͺ
minutes, cells were incubated on ice either with FACS buffer containing ʹͲͻ
unconjugated streptavidin (2 mg/ml, Life Technologies) or FACS buffer alone. ʹͳͲ
Following internalization, cells were either directly fixed with PFA (3%) or ʹͳͳ
incubated with FACS buffer supplemented with streptavidin and sodium azide ʹͳʹ
0.1% for 30 minutes and then fixed. For permeabilization Triton X-100 0.5% ʹͳ͵
diluted in PBS was used. For staining, Cy3-labeled streptavidin (Life ʹͳͶ
Technologies) diluted in FACS buffer was used. Sialic acid was stained using ʹͳͷ
Sambucus nigra and Maackia amurensis lectins (Reactolab SA). FACS analysis ʹͳ͸
was performed on a CyAn ADP Analyzer (Beckmann Coulter Inc.) and data were ʹͳ͹
analyzed using FlowJo software.  ʹͳͺ
ʹͳͻ
Fusion Assay. Measurement of viral fusion was performed according to the ʹʹͲ
protocol previously described in (32). In brief, IAV A/PR/8/34 was labeled using ʹʹͳ
two fluorescent dyes, R18 and SP-DiOC18 (Molecular Probes), in a ratio 1:2 with ʹʹʹ
final concentrations of R18=22 μM and SP-DiOC18=46 μM. After intense ʹʹ͵
vortexing for 1 hour labeled virus was filtered through a 0.22 μm pore filter. Virus ʹʹͶ
was cold-bound to the cells for 30 min and after washing with PBS temperature ʹʹͷ
was shifted to 37 °C for either 0, 90 or 180 minutes. Unfixed and ʹʹ͸
unpermeabilized samples were mounted with DAPI Fluoromount G and images ʹʹ͹
were acquired on a Leica SP5 confocal laser scanning mircroscope. Image ʹʹͺ
analysis was carried out using the spot analysis function of Image J for SP-ʹʹͻ
ͳͳ

DiOC18 staining with a distinct spot size of 20 pixels and a subsequent ʹ͵Ͳ
correction for cell numbers.ʹ͵ͳ
Resultsʹ͵ʹ
PEPD was identified as a potential entry factor during a virus-like particle ʹ͵͵
based entry screen. ʹ͵Ͷ
The above described genome-wide siRNA screens identified numerous factors to ʹ͵ͷ
be involved in IAV infection. To uncover potential entry factors of IAV, we ʹ͵͸
decided to revisit the primary hits of four published siRNA screens (24-26, 28) ʹ͵͹
that lacked experimental validation and screen them for a role during the IAV ʹ͵ͺ
entry process. We included only those factors that were identified during at least ʹ͵ͻ
two (or more) out of the four published screens in order to increase the ʹͶͲ
confidence of finding an association with IAV infection. As we were primarily ʹͶͳ
interested in virus entry we excluded factors with a known nuclear function such ʹͶʹ
as splicing factors (Fig 1A). The remaining 43 factors were screened for a role ʹͶ͵
during IAV entry using a virus-like particle (VLP)-based entry assay: We used ʹͶͶ
VLPs that carry IAV glycoproteins on their surface and contain a reporter gene ʹͶͷ
for convenient readout. These VLPs mimic IAV particles but carry a GaussiaʹͶ͸
luciferase reporter gene. Human lung A549 cells were transfected with siRNAs to ʹͶ͹
achieve knockdown of the respective candidate genes.  Per factor, four different ʹͶͺ
siRNAs were used to exclude off-target effects. 48 hours post-transfection, cells ʹͶͻ
were infected with VLPs and luciferase counts were measured 30 hours post-ʹͷͲ
infection as an indicator of entry efficiency. To counterscreen for non-entry ʹͷͳ
related effects, VLPs carrying the envelopes of Lassa virus (LASV) or Murine ʹͷʹ
ͳʹ

Leukemia virus (MLV) were included. LASV also enters target cells by ʹͷ͵
endocytosis but bypasses early steps of endosomal trafficking (33). In contrast, ʹͷͶ
MLV is known to enter target cells via membrane fusion (34). Entry factors were ʹͷͷ
defined as genes that, upon knockdown with at least two siRNAs, resulted in ʹͷ͸
inhibition of IAV-VLP entry but not of VLPs carrying glycoproteins of LASV or ʹͷ͹
MLV. In total, 22 factors were shown to be associated with IAV entry (Fig 1A and ʹͷͺ
B). We calculated an entry score that is based on the number of siRNAs per ʹͷͻ
gene that induced IAV-specific reduction of VLP entry and the degree of ʹ͸Ͳ
reduction compared to controls. The entry score was subsequently used to rank ʹ͸ͳ
the identified entry factors (Fig 1B). siRNAs targeting subunits of the endosomal ʹ͸ʹ
vATPase reduced IAV VLP entry most strongly (Fig 1B and C). The vATPase ʹ͸͵
mediates the acidification of endosomes and is known to be required for efficient ʹ͸Ͷ
entry of IAV (35, 36) thereby acting as internal control for our entry screen. ʹ͸ͷ
Another well-perfoming candidate was prolidase (PEPD), a ubiquitously ʹ͸͸
expressed cytosolic peptidase that cleaves dipeptides with a proline or ʹ͸͹
hydroxyproline at the C-terminus. Three out of four PEPD-specific siRNAs ʹ͸ͺ
potently reduced IAV VLP entry but not control VLPs (Fig 1C and Suppl. Table ʹ͸ͻ
1). Besides its dipeptidase function, PEPD has been shown to be involved in ʹ͹Ͳ
epidermal growth factor recetor (EGFR) family signalling (37, 38). EGFR ʹ͹ͳ
signalling is believed to play a role during IAV infections (39, 40). In addition, ʹ͹ʹ
gene ontology analysis of the validated hits of the siRNA screens revealed ʹ͹͵
kinase signalling as the most overrepresented category (31). Therefore, we ʹ͹Ͷ
chose PEPD as a candidate for follow-up studies. Efficient knockdown of ʹ͹ͷ
ͳ͵

endogenous as well as overexpressed PEPD protein levels were confirmed by ʹ͹͸
western blot (Fig 1D). Moreover, cell viability 48h after siRNA transfection was ʹ͹͹
assessed to exclude false-positive effects due to increased cell death (Fig 1E). ʹ͹ͺ
To exclude that siRNA transfection alone stimulated interferon (IFN) production, ʹ͹ͻ
thereby reducing VLP entry in PEPD knockdown cells due to expression of ʹͺͲ
antiviral genes, we detected protein levels of MxA, an IFN-inducible gene, in ʹͺͳ
A549 cells 48h after siRNA transfection. No MxA induction was observed in ʹͺʹ
siPEPD or siScr transfected cells. Only following stimulation with IFN, MxA was ʹͺ͵
detectable (Fig 1F). These data suggest that PEPD is required during the IAV ʹͺͶ
entry process and we therefore selected PEPD as a candidate for follow-up ʹͺͷ
studies on IAV entry.ʹͺ͸
PEPD is required for growth of IAV. ʹͺ͹
Next, we investigated whether knockdown of PEPD also affected growth of wild-ʹͺͺ
type IAV. We transfected A549 cells with siRNAs targeting PEPD or with a ʹͺͻ
control siRNA. Cells were infected with A/WSN/33 with a low MOI (0.01) to allow ʹͻͲ
multi-cycle growth. 24 hours post-infection, tissue culture supernatants were ʹͻͳ
harvested and viral titers were determined by plaque assay. Depletion of PEPD ʹͻʹ
reduced viral titers strongly compared to siScr transfected cells (Fig 2A). Similar ʹͻ͵
growth defects of A/WSN/33 were observed in WI38 cells, a primary lung ʹͻͶ
fibroblast cell line (Fig 2B). In addition, IAV strains FPV/Dobson (H7N7), A/Hong ʹͻͷ
Kong/68 (H3N2), A/Netherlands/602/2009 (H1N1) and A/Panama/2007/99ʹͻ͸
(H3N2) also displayed reduced growth in A549 cells upon PEPD knockdown (Fig ʹͻ͹
ͳͶ

2C-F), indicating that the observed phenotype is virus strain and cell line ʹͻͺ
independent.ʹͻͻ
Depletion of PEPD affects an early step during the IAV life cycle. ͵ͲͲ
To determine whether IAV growth is also affected during mono-cycle growth, we ͵Ͳͳ
monitored viral protein production 6h post infection in siRNA-treated A549 cells. ͵Ͳʹ
Knockdown of PEPD resulted in decreased protein levels of M1 in western blot ͵Ͳ͵
analysis (Fig 3A). Next, siRNA transfected A549 cells were infected with ͵ͲͶ
A/WSN/33 with a high MOI (10) for 3h and viral NP protein expression was ͵Ͳͷ
visualized by confocal microscopy. In siScr treated cells, a strong NP signal was ͵Ͳ͸
detected in the nuclei of infected cells (Fig 3B) while in cells depleted of vATPase ͵Ͳ͹
barely any nuclear NP was detectable. Following transfection of siRNAs targeting ͵Ͳͺ
PEPD, nuclear NP expression was largely absent, similar to vATPase ͵Ͳͻ
knockdown cells. The magnitude of NP-signal reduction was dependent of the ͵ͳͲ
siRNA used (Fig 3C). Transfection of siPEPD_1 inhibited the virus to a greater ͵ͳͳ
extent than siPEPD_2 and these data are consistent with the viral titers (Fig 2) ͵ͳʹ
and M1 expression levels (Fig 3A) measured before. In the presence of ͵ͳ͵
cycloheximide, when de novo synthesis of NP is blocked due to inhibition of ͵ͳͶ
protein biosynthesis, nuclear NP signal intensity was still lower in siPEPD_1 cells ͵ͳͷ
compared to control cells (Fig 3D). These data suggest that nuclear import of ͵ͳ͸
vRNPs is already impaired in the absence of PEPD.   ͵ͳ͹
Knockdown of PEPD reduces fusion events during IAV infection. ͵ͳͺ
ͳͷ

We next aimed to investigate whether the reduction of nuclear NP in PEPD ͵ͳͻ
knockdown cells was due to a defect in virus entry or due to a block during later ͵ʹͲ
events such as uncoating or transport of vRNPs into the nucleus. Therefore, we ͵ʹͳ
generated a dually fluorescent virus, labeled with SP-DiOC18 and R18 that ͵ʹʹ
allows the detection of fusion events. Both dyes are lipophilic and are inserted ͵ʹ͵
into the viral envelope upon labeling. This virus appears red fluorescent as the ͵ʹͶ
R18 dye (red) quenches the SP-DiOC18 dye (green) within the envelope of the ͵ʹͷ
virion (32). At the end of the viral entry process however, when viral and ͵ʹ͸
endosomal membranes merge, both dyes disperse within the endosomal ͵ʹ͹
membranes and the green fluorescent signal increases due to dequenching. To ͵ʹͺ
measure whether fusion is taking place in the absence of PEPD, we infected ͵ʹͻ
A549 cells 48h after siRNA transfection on ice with R18/SP-DiOC18-labelled ͵͵Ͳ
A/PR/8/34. Then, cells were shifted to 37°C for 0, 90 or 180 minutes to allow ͵͵ͳ
entry and fusion of the labeled viruses. During the experiment, either DMSO ͵͵ʹ
0.1% or 10 nM bafilomycin A1 was present in the medium. Bafilomycin A1 is an ͵͵͵
inhibitor of vATPases and prevents acidification of endosomes and thus blocks ͵͵Ͷ
IAV fusion (41). In control cells, large green fluorescent fusion sites were ͵͵ͷ
detectable after 90 and 180 minutes but not after 0 minutes of infection (Fig 4 A ͵͵͸
and B). Cells depleted of vATPase had a reduced number of fusion sites ͵͵͹
compared to siScr-treated cells. Also in siPEPD-transfected cells, significantly ͵͵ͺ
less fusion sites were counted following both, 90 minutes and 180 minutes of ͵͵ͻ
infection (Fig 4A and B). Treatment with bafilomycin A1 potently inhibited viral ͵ͶͲ
fusion in all cells tested (Fig 4C). These data strongly suggest that indeed, PEPD ͵Ͷͳ
ͳ͸

plays a role during the IAV entry process as fusion is impaired to comparable ͵Ͷʹ
levels to vATPase depleted cells. Thus, PEPD is required by the virus for efficient ͵Ͷ͵
fusion or earlier during entry. ͵ͶͶ
PEPD is not required for attachment or internalization of IAV. ͵Ͷͷ
We continued to identify the step affected during IAV entry in the absence of ͵Ͷ͸
PEPD. The first step of the entry process is the attachment of the virus to the ͵Ͷ͹
host cell membrane. To assess whether PEPD is required for receptor ͵Ͷͺ
expression we measured the amount of both, Į2’-3’ and Į2’-6’ linked sialic acid ͵Ͷͻ
expressed on the surface of A549 cells 48 hours after siRNA transfection. As ͵ͷͲ
depicted in Figure 5A, there was no difference in the amount of both types of ͵ͷͳ
receptors on PEPD knockdown cells compared to control cells as measured by ͵ͷʹ
FACS. We next investigated the effect of PEPD depletion on IAV attachment and ͵ͷ͵
internalization. Therefore, we generated biotinylated A/WSN/33 that can be ͵ͷͶ
visualized through staining with fluorescently labeled streptavidin. siPEPD or ͵ͷͷ
siScr transfected A549 cells were incubated on ice with this biotinylated virus, ͵ͷ͸
allowing only attachment of virions to the cell membrane but preventing ͵ͷ͹
internalization. Cell-bound virus was detected using cy3-labeled streptavidin. ͵ͷͺ
This signal was completely abrogated when cells were incubated with unlabeled ͵ͷͻ
streptavidin before fixation and subsequent staining (Fig 5B). There was no ͵͸Ͳ
difference detectable in the amount of virus attached to cells treated with siRNAs ͵͸ͳ
targeting PEPD or control siRNAs. In order to measure internalized particles, ͵͸ʹ
virus-attached cells were incubated at 37ºC for 30 minutes. Following incubation, ͵͸͵
cells were either treated with unlabeled streptavidin or PBS before fixation, ͵͸Ͷ
ͳ͹

permeabilization and staining with cy3-labelled streptavidin. External application ͵͸ͷ
of unlabeled streptavidin could only partially reduce the virus-derived signal ͵͸͸
indicating that most of the virions were taken up into the cells (Fig 5B). The ͵͸͹
relative amount of internalized virus was calculated as the ratio of virus detected ͵͸ͺ
after 30 minutes following unlabeled streptavidin incubation to virus detected ͵͸ͻ
after 30 minutes washed only with PBS (Fig 5C). Notably, similar amounts of ͵͹Ͳ
virus were internalized in siPEPD-treated cells in comparison to control cells. To ͵͹ͳ
confirm that virus uptake was not affected in the absence of PEPD we visualized ͵͹ʹ
SP-DiOC18-labeled A/WSN/33 after 30 minutes of infection. Z-stack images ͵͹͵
clearly revealed virus inside cells depleted of PEPD (Fig 5D). Taken together, we ͵͹Ͷ
were able to demonstrate that siRNA-mediated knockdown of PEPD does neither ͵͹ͷ
influence IAV attachment to target cells nor virus internalization. ͵͹͸
Incoming virus exhibits a different localization pattern in PEPD depleted ͵͹͹
cells.͵͹ͺ
Our data so far suggest that IAV requires PEPD during the entry process after ͵͹ͻ
internalization and before or during fusion. Next, we investigated trafficking of ͵ͺͲ
incoming virus particles in siRNA-treated cells deficient of PEPD. Cells were ͵ͺͳ
infected with A/WSN/33 with MOI of 25 and virus was visualized after 0, 30, 60, ͵ͺʹ
90, and 180 minutes through staining of NP which is very abundant in IAV virions ͵ͺ͵
(42). In control cells, IAV was detectable in the cytoplasm of infected cells at ͵ͺͶ
early time points (30 and 60 minutes post-infection) while after 90 and 180 ͵ͺͷ
minutes of infection, NP was also detectable in the cell nuclei (Fig 6A). The ͵ͺ͸
strong signal 180 post infection was largely due to de novo synthesis and could ͵ͺ͹
ͳͺ

be abrogated through treatment with cycloheximide (data not shown). ͵ͺͺ
Nevertheless, similar to the data presented in Figure 3D, NP was present in the ͵ͺͻ
nuclei of cells in the presence of the drug, indicating that nuclear import of ͵ͻͲ
vRNPs was effective in siScr-transfected cells. Following PEPD knockdown ͵ͻͳ
however, the distribution of PEPD was largely different to control cells: The NP ͵ͻʹ
signal appeared predominantly in the cell periphery during all time points ͵ͻ͵
measured (Fig 6A). Even after 180 minutes, only few nuclei showed de novo NP ͵ͻͶ
synthesis, this is in correspondence to the data presented in Figure 3B. Instead, ͵ͻͷ
most of the signal was visible in proximity to the plasma-membrane of the cells. ͵ͻ͸
This distinctive localization pattern of NP in siPEPD-transfected cells suggests ͵ͻ͹
that early virus sorting and trafficking within the endosomal compartment may be ͵ͻͺ
affected. The morphology and localization of early and late endosomes, ͵ͻͻ
visualized through staining of the respective markers EEA1 and LBPA, was ͶͲͲ
indistinguishable in cells treated with siPEPD or siScr (Fig 6B). In addition, ͶͲͳ
staining of the endocytic machinery using lysotracker, a fluorescent dye that ͶͲʹ
labels acidic organelles, did not reveal differences between siPEPD and control ͶͲ͵
treated cells indicating that the endosomal compartment remains intact in the ͶͲͶ
absence of PEPD (Fig 6B). We next investigated the degree of co-localization of ͶͲͷ
incoming virions with early and late endosome markers in a time-course ͶͲ͸
experiment (Fig 6 C-E). In control cells, NP co-localized with the early endosome ͶͲ͹
marker EEA1 during early phases of infection (Fig 6D) and subsequently with the ͶͲͺ
late endosomal marker LBPA (Fig 6E). In cells transfected with siRNAs targeting ͶͲͻ
vATPase, a higher degree of co-localizaton was observed for NP and EEA1 at ͶͳͲ
ͳͻ

early time points and with LBPA during late time points of infection (Fig 6D and Ͷͳͳ
E). This is in line with a previous report showing that depletion of vATPase Ͷͳʹ
results in accumulation of incoming viruses within endosomal compartments (43). Ͷͳ͵
In contrast, at all time points measured, less NP co-localized with either EEA1 or ͶͳͶ
LBPA in PEPD deficient cells (Fig 6D and E). The retention of larger amounts of Ͷͳͷ
virus in the cell periphery probably largely accounts for this observation. Taken Ͷͳ͸
together, we demonstrate that in the absence of PEPD, incoming IAV Ͷͳ͹
predominantly resides in the cell periphery leading to reduced association with Ͷͳͺ
early and late endosomes as well as limited nuclear import and de novo NP Ͷͳͻ
synthesis.ͶʹͲ
Cbz-Pro, an inhibitor of the enzymatic activity of PEPD inhibits IAV at an Ͷʹͳ
early step of the infection cycle. Ͷʹʹ
As PEPD possesses dipeptidase activity, we tested whether this catalytic activity Ͷʹ͵
mediates the proviral effects of PEPD. To this aim, we used Cbz-Pro, a ͶʹͶ
competitive inhibitor of PEPD catalytic activity (44). In human fibroblasts it has Ͷʹͷ
been shown that 10mM of Cbz-Pro inhibits PEPD enzymatic activity to about Ͷʹ͸
80% (45). Therefore, we decided to use 5 and 10 mM Cbz-Pro for our Ͷʹ͹
experiments. Following 2h of pre-incubation, A549 cells were infected on ice with Ͷʹͺ
A/WSN/33, MOI=10 in the presence of the inhibitor or control treatment. Then, Ͷʹͻ
cells were shifted to 37ºC for 3h with inhibitor present in the media. Nuclear NP Ͷ͵Ͳ
expression was monitored by confocal microscopy. Cbz-Pro reduced the amount Ͷ͵ͳ
of nuclear NP compared to cells treated with the solvent methanol (Fig 7A ). Ͷ͵ʹ
Treatment with 5mM Cbz-Pro had a small but significant effect on nuclear NP-Ͷ͵͵
ʹͲ

synthesis, while the higher concentration strongly inhibited nuclear NP signal (Fig Ͷ͵Ͷ
7A), indicating a dose-dependency. The reduction in NP signal was not due to Ͷ͵ͷ
cytotoxic effects of the inhibitor as shown in a cell viability assay for 5h treatment Ͷ͵͸
with the inhibitor (Fig 7B). Moreover, in the presence of cycloheximide, Cbz-Pro Ͷ͵͹
also reduced nuclear NP signal intensity, indicating that the inhibitor acts before Ͷ͵ͺ
viral protein synthesis (Fig 7C). We next tested whether bafilomycin A1 treatment Ͷ͵ͻ
following incubation with Cbz-Pro could maintain the inhibition of virus infection. ͶͶͲ
A549 cells were incubated with Cbz-Pro for 2h prior to infection with WSN. After ͶͶͳ
infection, cells were incubated in Cbz-Pro-containing medium for 1h at 37°C. ͶͶʹ
Then, cells were incubated either with Cbz-Pro, solvent or bafilomycin A1. 3h ͶͶ͵
post infection, nuclear NP signal intensity was measured by confocal microscopy. ͶͶͶ
As shown in figure 7D, switching from Cbz-Pro treatment to bafilomycin A1 1h ͶͶͷ
after infection resulted in a similar degree of inhibition as treatment with Cbz-Pro ͶͶ͸
for 3h. Switching from Cbz-Pro to solvent-containing medium in turn resulted in ͶͶ͹
markedly increased signal intensity of nuclear NP. These data indicate that Cbz-ͶͶͺ
Pro treatment indeed targets viral entry before fusion. Taken together, our data ͶͶͻ
indicate that the catalytic activity of PEPD is required for efficient entry of the ͶͷͲ
virus into target cells.Ͷͷͳ
PEPD has been shown to act as a ligand for members of the EGF receptor family Ͷͷʹ
when present in the extracellular space (37, 38). Furthermore, activation of Ͷͷ͵
EGFR has been implicated in IAV internalization (39). Therefore, we tested ͶͷͶ
whether extracellularly provided recombinant PEPD can rescue virus infection Ͷͷͷ
following siRNA-mediated knockdown of intracellular PEPD. 48h after Ͷͷ͸
ʹͳ

transfection of siScr or siPEPD_1, A549 cells were infected with IAV MOI=10 on Ͷͷ͹
ice and nuclear NP signal intensity was determined following incubation for 3h at Ͷͷͺ
37°C. It has been shown that 2.7nM PEPD suffices to activate EGFR (37). We Ͷͷͻ
decided to use 50nM PEPD during our experiments.  Recombinant PEPD or Ͷ͸Ͳ
vehicle was added to the medium either 1h before infection, during infection or Ͷ͸ͳ
1h post-infection and was maintained until the end of the experiment. As shown Ͷ͸ʹ
in figure 7E, extracellular PEPD was not able to restore nuclear NP levels in Ͷ͸͵
siPEPD_1 treated cells. Thus, the effect of depletion of intracellular PEPD on IAV Ͷ͸Ͷ
infection is independent of possible extracellular effects of PEPD on virus entry.Ͷ͸ͷ
Ͷ͸͸
Discussion Ͷ͸͹
In this study, we identify PEPD as a novel entry factor of IAV. We have Ͷ͸ͺ
demonstrated that upon knockdown of PEPD, IAV fusion events and the degree Ͷ͸ͻ
of co-localization with endosomal markers are strongly reduced. Instead, Ͷ͹Ͳ
incoming IAV is retained in proximity to the plasma membrane. This suggests Ͷ͹ͳ
that PEPD is required for early endosomal routing of IAV during entry. Ͷ͹ʹ
PEPD is a metalloprotease (46, 47) that catalyzes a rate-limiting step in the Ͷ͹͵
collagen-recycling pathway (48). During the degradation of collagen, PEPD Ͷ͹Ͷ
cleaves dipeptides containing a proline or hydroxyproline at the C-terminus, Ͷ͹ͷ
thereby releasing free proline into the cytoplasm (48, 49). Mutations that result in Ͷ͹͸
loss of enzymatic activity give rise to prolidase deficieny (PD), a rare autosomal Ͷ͹͹
recessive disease in humans. PD is a connective tissue disorder and comprises Ͷ͹ͺ
a variety of symptoms such as mental retardation, skin ulcerations and recurrent Ͷ͹ͻ
ʹʹ

respiratory infections (48, 50-52). PEPD overexpression induces the expression ͶͺͲ
of HIF-1Į-related gene products (53) as well as reduced NF-țB expression (48) Ͷͺͳ
thereby providing a link between PEPD and the regulation of immune responses Ͷͺʹ
such as cytokine production. In line with this, PD appears to be associated with Ͷͺ͵
systemic lupus erythematosus, an auto-immune disorder. Thus, the complexity of ͶͺͶ
the disorder and the apparent distortion of barrier as well as immune functions Ͷͺͷ
during long-term alteration of PEPD expression and -function may explain the Ͷͺ͸
increased susceptibility to infections. However, PEPD has also been Ͷͺ͹
demonstrated to be involved in a number of signaling pathways that are activated Ͷͺͺ
during early phases of IAV infection: PEPD activity has been shown to be Ͷͺͻ
positively regulated through Integrin-ȕ1 receptor signaling (54). Echistatin, a ͶͻͲ
dysintegrin and receptor antagonist of Integrin-ȕ1 (55), reduced PEPD activity Ͷͻͳ
and expression, as well as levels of phosphorylated MAPK1 and MAPK2 (56). Ͷͻʹ
Conversely, thrombin, an integrin activator, induced the opposite effects (56). Ͷͻ͵
Interestingly, MAPK1 was also shown to be activated during IAV infection in a ͶͻͶ
biphasic manner (57). The early phase phosphorylation was already apparent 5-Ͷͻͷ
30 minutes post-infection indicating that MAPK1 signaling is involved during IAV Ͷͻ͸
entry. In addition, inhibition of PEPD activity with Cbz-Pro was reported to Ͷͻ͹
decrease phospho-AKT and phospho-mTOR levels, while incubation of cells with Ͷͻͺ
the PEPD products proline and hydroxyproline reversed this effect (45). The Ͷͻͻ
AKT/mTOR signaling cascade has also been shown to be activated early during ͷͲͲ
IAV infection (58), indicating that IAV activates pathways that are positively ͷͲͳ
regulated by PEPD.  ͷͲʹ
ʹ͵

Moreover, a recent study by Yang and colleagues suggests that PEPD can bind ͷͲ͵
and activate EGFR and induce downstream signaling events (37). EGFR is a ͷͲͶ
receptor tyrosine kinase (RTK) that is upstream of MAPK1 and has been ͷͲͷ
implicated in IAV infection. During a recently published RNAi screen for host ͷͲ͸
factors of IAV, EGFR was one of the best performing candidates (29). In addition, ͷͲ͹
Eierhoff and colleagues have demonstrated that EGFR is activated following IAV ͷͲͺ
attachment, which in turn promotes uptake of virions into cells (39), thereby ͷͲͻ
providing evidence for a role of EGFR during IAV entry. Notably, PEPD only ͷͳͲ
activated EGFR when present in the extracellular space, e.g. through release ͷͳͳ
from injured cells. Similar data were obtained for ErbB2, a member of the EGF ͷͳʹ
receptor family (38). Our data in contrast indicate that the enzymatic activity of ͷͳ͵
PEPD may play a role for its pro-viral effects during IAV entry and that a step ͷͳͶ
following internalization but before fusion is affected after PEPD depletion and ͷͳͷ
inhibition of its enzymatic activity. Furthermore, our experiments using ͷͳ͸
recombinant PEPD indicate that extracellularly provided PEPD cannot ͷͳ͹
compensate for the depletion of intracellular PEPD and fails to rescue IAV ͷͳͺ
replication in cells treated with siRNAs targeting PEPD. Thus, to what extent ͷͳͻ
EGFR and other family members are involved in the PEPD-dependent regulation ͷʹͲ
of IAV entry remains to be determined. Our data together with other published ͷʹͳ
studies provide a link between PEPD activity, early signaling events induced by ͷʹʹ
IAV and the successful completion of IAV entry. However, further experiments ͷʹ͵
are required to elucidate the relationship between these events and their ͷʹͶ
contribution during IAV entry.ͷʹͷ
ʹͶ

Taken together, we were able to show that PEPD is required by IAV early in ͷʹ͸
infection and that in the absence of PEPD early viral trafficking events are altered ͷʹ͹
leading to reduced amounts of virus within early and late endosomes and fewer ͷʹͺ
fusion events. While systemically, PEPD may be involved in maintaining the ͷʹͻ
barrier function and immunity to infections; our data indicate that on the cellular ͷ͵Ͳ
level, PEPD is involved in orchestrating IAV routing during the entry process. ͷ͵ͳ
Nevertheless, the precise role of PEPD during IAV entry remains elusive and the ͷ͵ʹ
mechanism of the pro-viral role of PEPD during IAV entry will be the subject of ͷ͵͵
further studies.ͷ͵Ͷ
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Figure legends ͷͶͷ
Figure 1. Identification of PEPD through a screen for host factors involved ͷͶ͸
in IAV entry.ͷͶ͹
A Overview of the screening process. B Positive hits of the entry screen. The ͷͶͺ
darker the colour and the higher the entry score, the better was the performance ͷͶͻ
of a given factor during the entry screen. C vATPase and PEPD depletion ͷͷͲ
reduces entry of IAV VLPs. A549 cells transfected with siRNAs targeting ͷͷͳ
vATPase or PEPD were infected with VLPs carrying IAV, LASV or MLV ͷͷʹ
glycoproteins on their surface and encoding a luciferase reporter gene. ͷͷ͵
Luciferase activity was measured at 30h post infection and luciferase of cells ͷͷͶ
transfected with siScr was set to 100%. Error bars indicate standard deviation of ͷͷͷ
triplicates. D PEPD Knockdown control. A549 cells were either transfected with ͷͷ͸
siRNAs targeting PEPD or siScr alone, or co-transfected with siRNAs and a ͷͷ͹
PEPD expression plasmid. PEPD protein levels after 48h were determined by ͷͷͺ
western blot. Arrow indicates endogenous PEPD. Shown is a representative ͷͷͻ
image of three independent experiments. E Cytotoxicity of PEPD-specific ͷ͸Ͳ
siRNAs 48h post-transfection. Values are relative to cells transfected with siScr. ͷ͸ͳ
Error bars indicate standard deviation of triplicates. F Knockdown of PEPD does ͷ͸ʹ
not induce MxA expression. A549 cells were transfected with siPEPD_1 or siScr. ͷ͸͵
As positive control, siScr-transfected control cells were stimulated with IFN-Įͷ͸Ͷ
(100 U/ml) for 16h. 48h post-transfection MxA expression was measured by ͷ͸ͷ
western blot.ͷ͸͸
ʹ͸

Figure 2. PEPD is required for growth of different IAV strains.ͷ͸͹
A A/WSN/33 growth in A549 cells is reduced upon PEPD depletion. A549 cells ͷ͸ͺ
were transfected with siRNAs against PEPD, NP or siScr. 48h post-transfection ͷ͸ͻ
cells were infected with A/WSN/33 MOI=0.01. 24h post-infection, supernatants ͷ͹Ͳ
were harvested and viral growth was determined by plaque assay.Shown is one ͷ͹ͳ
of three independent experiments performed in triplicates. Error bars indicate ͷ͹ʹ
standard deviation. B Growth of A/WSN/33 in siRNA-transfected WI38 cells. ͷ͹͵
Protocol as in (A) but WI38 cells were used. Virus titers were measured in tissue ͷ͹Ͷ
culture supernatants 24h and 48h post-infection.Shown is one out of three ͷ͹ͷ
independent experiments. Error bars indicate standard deviation of triplicates. C-ͷ͹͸
F Growth of different IAV strains in A549 cells transfected with siScr, siPEPD_1 ͷ͹͹
or sivATPase.  48h post-transfection, cells were infected with FPV/Dobson ͷ͹ͺ
(H7N7) with MOI=0.01 (C), A/Hong Kong/68 (H3N2) with MOI=1 (D), ͷ͹ͻ
A/Netherlands/602/2009 (H1N1) with MOI=1 (E) or A/Panama/2007/99 (H3N2) ͷͺͲ
with MOI=1 (F). 24h later, supernatants were harvested and viral titers were ͷͺͳ
determined by plaque assay. Shown is one out of three independent experiments ͷͺʹ
performed in duplicates. Error bars indicate standard deviation. ͷͺ͵
Figure 3. Depletion of PEPD affects an early step of the IAV life cycle.  ͷͺͶ
A Early M1 expression is reduced by PEPD knockdown.  A549 cells were ͷͺͷ
transfected with siRNAs targeting PEPD or siScr. 48h post-transfection, cells ͷͺ͸
were infected with A/WSN/33 MOI=1. 6h after infection, cells were lyzed and M1 ͷͺ͹
expression was determined by western blot. B Immunofluorescence pictures ͷͺͺ
ʹ͹

showing reduced nuclear NP signal in PEPD knockdown cells. siRNA transfected ͷͺͻ
A549 were infected on ice with A/WSN/33 MOI=10 for 1h. Then, cells were ͷͻͲ
incubated at 37°C for additional 3h. Cells were stained for NP expression (green) ͷͻͳ
and nuclei (blue) and analyzed by confocal microscopy. Scale bars equal 25 μm. ͷͻʹ
Shown are representative pictures of three independent experiments performed ͷͻ͵
in duplicates. C Quantification of (B). Nuclear NP signal intensity of 100 nuclei ͷͻͶ
per condition was quantified using ImageJ software and analyzed using the ͷͻͷ
Mann-Whitney test. Error bars indicate standard deviation. D Quantification of ͷͻ͸
imported nuclear NP. Experimental set-up as in (B) but during the experiment, ͷͻ͹
cycloheximide (100ug/ml) was present in the media. 87 nuclei were counted per ͷͻͺ
condition and analyzed using the Mann-Whitney test. Error bars indicate ͷͻͻ
standard deviation. ͸ͲͲ
Figure 4. Knockdown of PEPD reduces fusion events during IAV infection. ͸Ͳͳ
A Reduced fusion of SP-DiOC18/R18-labelled virus in PEPD-depleted cells. ͸Ͳʹ
A549 cells were transfected with siRNAs targeting PEPD, vATPase or with siScr. ͸Ͳ͵
48h post-transfection cells were first pre-incubated with 10 nM bafilomycin A1 or ͸ͲͶ
0.1% DMSO and then infected on ice with SP-DiOC18/R18-labelled A/PR/8/34 ͸Ͳͷ
for 1h. After incubation at 37°C for 0, 90 or 180 min cells were analyzed by ͸Ͳ͸
confocal microscopy. Shown are images representative of the 90 minutes time ͸Ͳ͹
point from the DMSO-treated samples. Scale bars equal 10 μm. B and C͸Ͳͺ
Quantification of (A).The number of fusion sites per cell was quantified using ͸Ͳͻ
ImageJ software. Cells treated with DMSO are shown in (B). Cells treated with ͸ͳͲ
ʹͺ

bafilomycin A1 (10nM) are depicted in (C). (B) and (C) show a quantification of ͸ͳͳ
one out of three independent experiments. Error bars indicate standard deviation.  ͸ͳʹ
Figure 5. Effect of PEPD knockdown on sialic acid expression, IAV ͸ͳ͵
attachment and uptake.  ͸ͳͶ
A PEPD knockdown does not influence surface sialic acid expression. A549 cells ͸ͳͷ
were treated with siRNAs against PEPD or with siScr, stained with Sambucus͸ͳ͸
nigra  or Maackia amurensis lectins recognizing either Į2’-3’ or Į2’-6’ sialic acid ͸ͳ͹
and analyzed by FACS. Shown is one out of three independent experiments. Per ͸ͳͺ
condition, 10000 cells were analyzed. B and C Virus attachment and ͸ͳͻ
internalization are not affected by PEPD knockdown. A549 cells were transfected ͸ʹͲ
with siRNAs targeting PEPD or siScr and were infected 48h later on ice with ͸ʹͳ
biotinylated A/WSN/33 for 1h. Cells were either fixed following infection or, virus ͸ʹʹ
was allowed to internalize for 30 minutes at 37ºC. In half of the samples plasma ͸ʹ͵
membrane-attached virus was masked using unlabeled streptavidin before ͸ʹͶ
permeabilization (+ strep). The other half was PBS treated. Following ͸ʹͷ
permeabilization, cells were stained with Cy3-labelled streptavidin and analyzed ͸ʹ͸
by FACS (B). The relative amount of internalized virus was calculated as the ratio ͸ʹ͹
of virus-positive cells at ‚30 min + strep‘ to ‚30 min without strep‘ (C).  Shown is ͸ʹͺ
one out of three independent experiments. Per condition, 10000 cells were ͸ʹͻ
analyzed. D Visualization of IAV internalization. SP-DiOC18-labelled IAV was ͸͵Ͳ
allowed to cold-bind to siScr or siPEPD treated A549 cells. Then, temperature ͸͵ͳ
was shifted to 37°C. After 30 minutes, cells were fixed and Į2’-6’ linked sialic ͸͵ʹ
acid on the cell surface was stained using Sambucus nigra lectin. Images were ͸͵͵
ʹͻ

taken using confocal microscopy. Scale bars equal 10 μm. Arrows indicate ͸͵Ͷ
DiOC18-labeled, internalized virus. Representative images are shown. ͸͵ͷ
Figure 6. Incoming virus exhibits a different localization-pattern in PEPD ͸͵͸
knockdown cells.  ͸͵͹
A Immunofluorescence pictures showing NP distribution in PEPD-depleted and ͸͵ͺ
control cells. A549 cells were transfected with siScr or siPEPD_1. 48 hours post-͸͵ͻ
transfection, cells were infected with A/WSN/33 with MOI=25. At the indicated ͸ͶͲ
time points, cells were fixed, stained for viral NP and analyzed by confocal ͸Ͷͳ
microscopy. Scale bars equal 25 μm. Shown is one out of three independent ͸Ͷʹ
experiments. B Effect of PEPD knockdown on the morphology of the endocytic ͸Ͷ͵
machinery. siRNA-transfected A549 cells were either stained for EEA1or LBPA ͸ͶͶ
or incubated with lysotracker reagent. Scale bars equal 10 μm. Representative ͸Ͷͷ
images of two independent experiments are shown. C Incoming viruses display ͸Ͷ͸
less co-localization with endosomes in PEPD-depleted cells. Experimental set-up ͸Ͷ͹
as in (A). Cells were co-stained against NP (green) and either EEA1 or LBPA ͸Ͷͺ
(red). Shown are representative images of virus-infected cells after 30 minutes ͸Ͷͻ
(EEA1) or 60 minutes (LBPA). Scale bars equal 10 μm.  D and E Co-localization ͸ͷͲ
quantification of the EEA1 (D) and LBPA (E) staining. Confocal images were ͸ͷͳ
analyzed for co-localization using Imaris software. The Mann-Whitney test was ͸ͷʹ
used to test for statistical significance (siScr vs. siPEPD_1). Shown is one out of ͸ͷ͵
three independent experiments. Error bars indicate standard deviation. ͸ͷͶ
͵Ͳ

Figure 7. Inhibition of PEPD enzymatic function restricts IAV early in ͸ͷͷ
infection.͸ͷ͸
A Nuclear NP expression in Cbz-Pro-treated cells. A549 cells were pre-treated ͸ͷ͹
for 2h with indicated amounts of Cbz-Pro or the solvent 0.5% MetOH. Cells were ͸ͷͺ
infected on ice with A/WSN/33 MOI=10 and afterwards shifted to 37ºC for ͸ͷͻ
additional 3h. During infection and later incubation the respective compounds ͸͸Ͳ
were present in the media. Cells were stained against NP and analyzed by ͸͸ͳ
confocal micoscropy. Mean nuclear intensity was quantified using Image J ͸͸ʹ
software. Mann-Whitney test was used for statistical comparison. Shown is one ͸͸͵
of three independent experiments. Error bars indicate standard deviation of 100 ͸͸Ͷ
quantified nuclei. B Cell viability. Cytotoxic effects of Cbz-Pro treatment were ͸͸ͷ
assessed in A549 cells following incubation for 5h. C Effect of Cbz-Pro on ͸͸͸
nuclear NP levels in the presence of cycloheximide. Experimental set-up as in ͸͸͹
(A). MOI=50 was used for infection and 100 ug/ml cycloheximide-containing͸͸ͺ
medium was added after infection. D Sequential treatment with Cbz-Pro and ͸͸ͻ
bafilomycin A1 inhibits nuclear NP expression. A549 cells were pre-incubated ͸͹Ͳ
with 10mM Cbz-Pro or 0.5% MetOH for 2h before infection on ice with A/WSN/33 ͸͹ͳ
MOI=10 in the presence of the inhibitor or solvent. After infection, cells were ͸͹ʹ
shifted to 37°C for 3h. 1h post-infection, Cbz-Pro or MetOH was present in the ͸͹͵
media. Following 30 min of incubation with both, Cbz-Pro and bafilomycin A1 ͸͹Ͷ
(10nM) or MetOH, cells were further incubated with bafilomycin A1 or MetOH-͸͹ͷ
containing medium for additional 90 min. Nuclear NP was measured and ͸͹͸
quantified as described above. Shown is one out of three independent ͸͹͹
͵ͳ

experiments with error bars indicating standard deviation of 100 analyzed nuclei.͸͹ͺ
E Extracellular PEPD cannot rescue IAV infection in siPEPD-treated cells. A549 ͸͹ͻ
cells were transfected with siScr or siPEPD_1. 48h post-transfection, cells were ͸ͺͲ
treated with 50nM of recombinant PEPD 1h before, 1h after or during infection ͸ͺͳ
with A/WSN/33 MOI=10. Following addition, PEPD was present in the media until ͸ͺʹ
3h after infection. Nuclear NP was measured and analyzed as described above. ͸ͺ͵
Shown is one out of three independent experiments with error bars indicating ͸ͺͶ
standard deviation of 100 quantified nuclei.  ͸ͺͷ
͸ͺ͸
͵ʹ

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